FDA Approves AstraZeneca’s IMFINZI Regimen for Bladder Cancer
The FDA approved perioperative IMFINZI with neoadjuvant enfortumab vedotin-ejfv, followed by adjuvant IM.
The FDA approved perioperative IMFINZI with neoadjuvant enfortumab vedotin-ejfv, followed by adjuvant IM.